Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Is there a cloud in the silver lining for imatinib?

S C Paterson1, K D Smith, T L Holyoake

  • 1Department of Bioscience, Royal College, University of Strathclyde, Glasgow, UK.

British Journal of Cancer
|April 3, 2003
PubMed
Summary

Imatinib mesylate offers targeted cancer therapy but faces drug resistance. Understanding resistance mechanisms like gene amplification and stem cell quiescence is crucial for developing new treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sequential BCR::ABL1 evaluation during dose de-escalation in peripheral blood is more predictive of TFR success than single assessment at dose de-escalation in either peripheral blood or bone marrow.

Leukemia·2026
Same author

Effect of the use of an iPad on the attention span of a child with Smith Magenis Syndrome: A single case study.

Journal of intellectual disabilities : JOID·2021
Same author

Investigation of fibrillin microfibrils in the canine cruciate ligament in dogs with different predispositions to ligament rupture.

Research in veterinary science·2020
Same author

A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.

Leukemia·2020
Same author

An investigation of targeted inhibition of transcription factor activity with pyrrole imidazole polyamide (PA) in chronic myeloid leukemia (CML) blast crisis cells.

Bioorganic & medicinal chemistry letters·2019
Same author

Acute Cardiotoxicity After Daunorubicin in Acute Myeloid Leukaemia.

Leukemia & lymphoma·2016

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Imatinib mesylate represents a breakthrough in molecularly targeted cancer therapy.
  • Chronic myeloid leukemia treatment has been revolutionized by tyrosine kinase inhibitors.
  • Drug resistance remains a significant challenge in oncotherapy.

Purpose of the Study:

  • To review the clinical promise of imatinib mesylate.
  • To explore the mechanisms of imatinib resistance.
  • To discuss potential strategies for overcoming drug resistance.

Main Methods:

  • Literature review of clinical and laboratory studies.
  • Analysis of divergent mechanisms of imatinib resistance.
  • Evaluation of current and future therapeutic approaches.

Related Experiment Videos

Main Results:

  • Imatinib resistance can arise through gene amplification.
  • Stem cell quiescence is another key mechanism of resistance.
  • Polychemotherapy is a considered but potentially insufficient strategy.

Conclusions:

  • While imatinib offers targeted oncotherapy, resistance is an inherent challenge.
  • Novel therapeutic strategies beyond polychemotherapy are needed.
  • Further research into resistance mechanisms is essential for advancing cancer treatment.